| Sagent Pharmaceuticals |
25021019111 |
Micafungin Injection (100mg 1x10) |
2022-10-25 |
1870.0000 |
No amount spent on marketing |
None |
2083 |
None |
None |
None |
None |
None |
None |
None |
None |
| Sagent Pharmaceuticals |
25021019011 |
Micafungin Injection (50mg 1x10) |
2022-10-25 |
935.0000 |
No amount spent on marketing |
None |
2083 |
None |
None |
None |
None |
None |
None |
None |
None |
| Sandoz Inc. |
00781808532 |
PIRFENIDONE 267MG 270FCT BO US |
2022-05-02 |
9130.5700 |
This launch is specific to the U.S. Sandoz Inc. is contracting within the wholesaler and/or specialty pharmacy space. The WAC is priced lower than the WAC of the reference product. |
None |
100000 |
None |
None |
None |
None |
None |
None |
According to Cortellis data from July 2021, IPF is rare disease, with an estimated prevalence of 44,000 to 135,000 cases and an incidence of 21,000 new cases per year in the U.S.
Source: https://insights.decisionresourcesgroup.com/disease/idiopathic-pulmonary-fibrosis.
Acquisition date and acquisition price not applicable; Sandoz Inc. did not acquire the product.
Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
None |
| Sandoz Inc. |
00781808692 |
PIRFENIDONE 801MG 90FCT BO US |
2022-05-02 |
9130.5700 |
This launch is specific to the U.S. Sandoz Inc. is contracting within the wholesaler and/or specialty pharmacy space. The WAC is priced lower than the WAC of the reference product. |
None |
100000 |
None |
None |
None |
None |
None |
None |
According to Cortellis data from July 2021, IPF is rare disease, with an estimated prevalence of 44,000 to 135,000 cases and an incidence of 21,000 new cases per year in the U.S.
Source: https://insights.decisionresourcesgroup.com/disease/idiopathic-pulmonary-fibrosis.
Acquisition date and acquisition price not applicable; Sandoz Inc. did not acquire the product.
Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
None |
| Sandoz Inc. |
00781351990 |
PEMETREXED FOR INJ 500MG/20ML |
2022-06-07 |
3369.1700 |
This launch is specific to the U.S. Sandoz Inc. is contracting within the oncology and hospital space. The WAC is priced lower than the WAC of the reference product. |
None |
53482 |
None |
None |
None |
None |
None |
None |
According to Decision Resources Group, now part of Clarivate, an estimated 53,482 patients in 2022 are treated with pemetrexed, (all branded and generic prescriptions, not just Sandoz) for non-small cell lung cancer (NSCLC) in the United States.
Acquisition date and acquisition price not applicable; Sandoz Inc. did not acquire the product.
Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
None |
| Sandoz Inc. |
00781349895 |
ARSENIC TRIOXIDE 12MG/6ML 6ML 10LIVI |
2022-07-14 |
4784.4000 |
This launch is specific to the U.S. Sandoz Inc. is contracting within the oncology and hospital space. The WAC is priced lower than the WAC of the reference product. |
None |
39743 |
None |
None |
None |
None |
None |
None |
According to Decision Resources Group, now part of Clarivate, an estimated 39,743 patients in 2022 are treated for Acute Myeloid Leukemia.
Acquisition date and acquisition price not applicable; Sandoz Inc. did not acquire the product.
Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
None |
| Sanofi |
80203034701 |
ENJAYMO® (Sutimlimab-jome) |
2022-02-21 |
1800.0000 |
In the US, marketing initiatives are expected to include print and digital media, engagement at scientific meetings attended by HCPs most likely to manage patients with CAD, materials to be used by sales representatives to share information on Enjaymo with prescribers, and materials to educate patients about CAD and Enjaymo. Direct to Consumer (DTC) outreach for Enjaymo will include search, website and online ad placements. DTC initiatives are not expected to include any TV, radio or national magazine advertising.
Ex-US, marketing initiatives are expected to include print and digital media, engagement at scientific meetings attended by HCPs most likely to manage patients with CAD, materials to be used by sales representatives to share information on Enjaymo with prescribers, and materials to educate patients about CAD and Enjaymo.
Sanofi’s commitment to pricing rests on three pillars: a holistic assessment of value when setting launch prices, year-over-year price increases that are limited to National Health Expenditure projections, and disclosure of our aggregate gross and net prices changes to provide greater transparency about the pricing of our medicines.
Given the growing concerns over rising health care costs, our approach to pricing reflects our commitment to patient access while minimizing our contribution to health care inflation. Sanofi has a longstanding commitment to promote health care systems that make our treatments accessible and affordable to patients in need
Sanofi understands and shares concerns about the affordability of medicines for patients while also recognizing that we are only one of many stakeholders in the health care system. While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. |
None |
4000 |
1 |
1 |
None |
None |
None |
None |
In the United States, it is estimated that there are ~5,000 people living with Cold Agglutinin Disease. While there are no US-specific population-based studies, national studies in European countries estimate a prevalence between 12-16 cases per million (Bylsma 2019, Berentsen 2006). CAD is a chronic autoimmune hemolytic anemia caused by an auto-antibody that targets red blood cells. The amount of autoimmune hemolytic anemia that a patient experiences will differ between patients and is in part determined by the temperature at which the cold agglutinin binds to the patients red blood cells. As a result, patients may experience mild, moderate or severe levels of anemia with intermittent exacerbations of symptoms and anemia. While Enjaymo is indicated for the treatment of all CAD patients regardless of severity, physicians may prefer to reserve pharmacologic treatment for symptomatic patients. In observational studies, the proportion of patients observed experiencing moderate to severe levels of anemia ranged from ~ 45% to 80% (Mullins 2017). Under the assumption that these patients are more likely to be symptomatic, the potential number of patients prescribed Enjaymo may range from 2,250 to 4,000. |
None |
| Sanofi |
58468005001 |
XENPOZYME™ (olipudase alfa-rpcp) for injection, for intravenous use |
2022-09-12 |
7142.0000 |
Marketing initiatives are expected to include print and digital media, engagement at scientific meetings attended by HCPs most likely to manage patients with acid sphingomyelinase deficiency (ASMD) disease, materials to be used by sales representatives to share information on XENOPZYME™ with prescribers, and materials to educate patients about ASMD and XENOPZYME™. Direct to Consumer (DTC) outreach for XENOPZYME™ will include search, website, online ad placements, email, and webinars. DTC initiatives are not expected to include any TV, radio, or national magazine advertising.
Sanofi’s commitment to pricing rests on three principles: a holistic assessment of value when setting launch prices, year-over-year price increases that are limited to National Health Expenditure projections, and disclosure of our aggregate gross and net prices changes to provide greater transparency about the pricing of our medicines. These comprehensive principles were drafted to address questions around the price of medicines in the United States. Our goal is to make our medicines accessible and affordable to all patients.
Given the growing concerns over rising health care costs, our approach to pricing reflects our commitment to patient access while minimizing our contribution to health care inflation. Sanofi has a longstanding commitment to promote health care systems that make our treatments accessible and affordable to patients in need?.
Sanofi understands and shares concerns about the affordability of medicines for patients while also recognizing that we are only one of many stakeholders in the health care system. While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. |
None |
1339 |
1 |
1 |
None |
None |
None |
None |
Historically, referred to as Niemann-Pick disease (NPD) types A, A/B, and B, acid sphingomyelinase deficiency (ASMD) is a rare, progressive genetic disease with significant morbidity and mortality. XENPOZYME™ is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved treatment for this disease. www.rarediseases.org estimates ASMD prevalence at 1 in 250,000. Based on the US population in 2023, the estimated number of patients in the US with ASMD for which XENPOZYME™ may be prescribed is 1,339. However, because some cases go misdiagnosed or undiagnosed, determining the true frequency of ASMD in the general US population is difficult. It has been estimated that there are fewer than 120 patients diagnosed with ASMD in the U.S. Approximately two-thirds of patients with ASMD in the U.S. are pediatric. |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=670 |
| Santen US |
65086000112 |
Verkazia .01% |
2022-05-02 |
1465.0000 |
This drug is addressing a rare disease within VRC market. There are estimated to be around 115k patients at any given time within the US. The WAC price is based upon modeling of this market within the US. product is the first drug specially indicated for this condition. |
None |
115000 |
1 |
None |
None |
None |
None |
None |
None |
None |
| Secura Bio, Inc. |
07311622556 |
Copiktra 25 mg oral capsule, 56 capsules per package, Secura labeler code |
2022-07-01 |
18074.3100 |
None |
1 |
200000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Slayback Pharma LLC |
71225012001 |
VIVIMUSTA- bendamustine hydrochloride injection 100mg/4mL, 4 mL in 1 VIAL |
2022-12-22 |
3209.5400 |
None |
1 |
8300 |
None |
None |
None |
None |
None |
None |
This product was not acquired. |
None |
| SpecGx |
00406771160 |
Noxafil (posaconazole) |
2022-07-18 |
970.0000 |
None |
1 |
2500 |
None |
None |
None |
None |
None |
None |
Consistent with Section 127681(c) of the California Health and Safety Code with respect to average number of patients, the information is not otherwise in the public domain or publicly available. Noxafil is used in the treatment of fungal infections, this number is an estimate of the number of patients that the product may be used for in the state. This is a generic product, not marketed directly to consumers or healthcare professionals. WAC price is based upon an analysis of existing generic and brand WAC prices. The details of this analysis are considered proprietary information. |
None |
| Spectrum Pharmaceuticals, Inc. |
76961010101 |
Rolvedon 13.2 mg/0.6 mL solution 1 prefilled syringe |
2022-10-18 |
4500.0000 |
Marketing: Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Educational materials will be provided to HCPs along with being available on the product website, and highlight access and affordability support for Rolvedon to ensure appropriate access to therapy.
Pricing: Rolvedon is an injectable drug administered subcutaneously after cytotoxic chemotherapy by healthcare professionals (i.e., a Part B drug), not a tablet, capsule, or similar self-administered drug covered by Part D. Rolvedon’s WAC is comparable to that of other drugs indicated for similar conditions, and is priced responsibly taking into account Rolvedon’s development costs; complex manufacturing (Rolvedon is a biologic); distribution and storage requirements (Rolvedon is a cold-chain product); and Spectrum’s ongoing operational costs (G&A, overhead) and patient assistance/support programs. |
None |
150000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Strides Pharma, Inc. |
64380015301 |
VALGANCICLOVIR 450MG TAB 60-STR |
2022-09-07 |
1009.5900 |
Marketed as a generic. WAC has been reduced considerably to match competition since launch |
None |
720 |
None |
None |
2022-06-01 |
133333.0000 |
None |
None |
None |
None |
| Strides Pharma, Inc. |
64380018901 |
Zileuton ER Tablets 600mg, 120ct |
2022-12-31 |
1500.0000 |
None |
1 |
1200 |
None |
None |
None |
None |
None |
None |
None |
None |
| SUN PHARMACEUTICALS |
62756006483 |
Fingolimod Oral Capsule 0.5MG, 30 count |
2022-10-25 |
2220.9700 |
None |
1 |
296700 |
None |
None |
None |
None |
None |
None |
None |
None |